Table 3.
Number of Patients Ending First Antiretroviral Regimen by Reason of Ending in the Cohort and Stratifying by late ART Initiation
| All | Non-LI | LI | ||||
|---|---|---|---|---|---|---|
| EFV-Based (n = 12 898), n (%) |
Boosted PI (n = 1621), n (%) |
EFV-Based (n = 5035), n (%) |
Boosted PI (n = 817), n (%) |
EFV-Based (n = 7863), n (%) |
Boosted PI (n = 804), n (%) |
|
| Patients ending firstline ART | 6914 (53) | 928 (57) | 2378 (42) | 449 (50) | 4536 (58) | 479 (59) |
| Reason of ending | ||||||
| Death | 821 (12) | 77 (8) | 149 (6) | 15 (3) | 672 (15) | 62 (13) |
| LTFU | 3040 (44) | 343 (37) | 1190 (50) | 184 (41) | 1850 (41) | 159 (33) |
| Changes of third componenta | 2894 (42) | 491(53) | 978 (41) | 238 (53) | 1916 (42) | 253 (53) |
| Treatment failure | 1866 (27) | 340 (37) | 595 (25) | 179 (40) | 1271 (28) | 161 (34) |
| Other reasons | 1028 (15) | 155 (17) | 383 (16) | 59 (13) | 645 (14) | 92 (19) |
Percentages for reason of ending are relative to the total number of ending firstline ART.
Abbreviations: EFV, efavirenz; firstline ART, first antiretroviral regimen; LI, patients initiating with CD4 <200 cells/µL or AIDS-defining event; LTFU, lost to follow-up, defined as no visits in the year before the closing date of data set in each site; Non-LI, patients initiating with CD4 ≥200 cells/µL and no AIDS-defining event; PI, protease inhibitor.
aChanges of third component include changes for any reason; in this table, we show the changes due to treatment failure, which could be documented virological failures and virological or treatment failures recorded as reason for change. Other reasons include toxicity and drug interactions, and changes with reason unknown. ART interruption is defined as interruptions longer than 180 days.